• 10 Years of passion!

    2015 we celebrated our jubilee: 10 years Targos!

  • Targos projectmanagement Team and Targos building

  • Targos Lab Team

  • Targos Logistics Team

  • Targos Advance Team

  • Targos Study Office Team

  • Targos employees and Targos building

  • Expert Training by Targos

  • Expert Training - microscope room

Targos - a Leader
in Customer-Oriented Biomarker Services

Targos GmbH building and staff 2015

Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry.

The company has supported more than 100 international clinical trials since 1999, which have led to the successful approval of several targeted therapies and IVDs for our customers.

The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). As of June 2013, Targos Molecular Pathology GmbH has met all applicable standards for accreditation and is accredited by the College of American Pathologists (CAP). As of January 2014 Targos is enrolled in the CLIA program.

Targos News


Prof. Bharat Jasani

Prof. Bharat Jasani, BSc (Hons), PhD., MBChB, FRCPath joins Targos as Director of Pathology.

Feb. 1, 2016:

"We are very proud to welcome Prof. Bharat Jasani, former Head of Dept. of Pathology at Cardiff University in our team. As Director of Pathology he will significantly strengthen our long-standing expertise in IHC and ISH based Biomarker testing  (validation, services and training)."

Prof. Josef Rueschoff

Prof. Dr. med. Josef Rüschoff
Chief Medical Officer
Targos Molecular Pathology GmbH
Click here to view


Novel route to serum based Prostate Cancer Diagnostics

Feb. 11, 2016:

Protagen AG, technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases and oncological indications, announced today the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine. Using the proprietary Protagen SeroTag® technology, the discovery was made in close collaboration with Professor Helmut Klocker, Medical University of Innsbruck and Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, Professor Mark Rubin, Cornell University and Targos Molecular Pathology GmbH, Kassel.

»Read more